In September 2020, the U.S. Food and Drug Administration announced a requirement that the Boxed Warningand other sections of benzodiazepine drug products’ labeling be updated to provide a more comprehensive description of risks related to nonmedical use, addiction, physical dependence, and withdrawal reactions. Benzodiazepine nonmedical use is widespread, andindividuals frequently couse benzodiazepines with alcohol, prescription opioids, and illicit drugs. Associated harms of benzodiazepine nonmedical use are substantial but occur primarily when people use benzodiazepines in combination with other drugs.This twoday public workshop will convene regulators, academic researchers, clinicians, patient advocates, and other stakeholders to share information underlying this action and gather input related to the safe use of benzodiazepines. Participants will discuss epidemiological and abuse liability data, patient and clinician perspectives and experiences, and gaps in data and understanding about the safe use of benzodiazepines.